a. College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China;
b. School of Pharmacy, Hebei Medical University, Shijiazhuang, 050017, China;
c. Department of Pharmacy, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China;
d. School of Science, China Pharmaceutical University, Nanjing, 210009, China
Funds:
This work was financially supported by National Natural Science Foundation of China (Grant No.: 82404511), Postdoctoral Fellowship Program of China Postdoctoral Science Foundation (CPSF) (Grant No.: GZC20232345), Priority-Funded Postdoctoral Research Project, Zhejiang Province, China (Grant No.: ZJ2024012), and Central Guidance on Local Science and Technology Development Fund of Hebei Province, China (Grant No.: 226Z2605G).
Advancements in artificial intelligence (AI) and emerging technologies are rapidly expanding the exploration of chemical space, facilitating innovative drug discovery. However, the transformation of novel compounds into safe and effective drugs remains a lengthy, high-risk, and costly process. Comprehensive early-stage evaluation is essential for reducing costs and improving the success rate of drug development. Despite this need, no comprehensive tool currently supports systematic evaluation and efficient screening. Here, we present druglikeFilter, a deep learning-based framework designed to assess drug-likeness across four critical dimensions: 1) physicochemical rule evaluated by systematic determination, 2) toxicity alert investigated from multiple perspectives, 3) binding affinity measured by dual-path analysis, and 4) compound synthesizability assessed by retro-route prediction. By enabling automated, multidimensional filtering of compound libraries, druglikeFilter not only streamlines the drug development process but also plays a crucial role in advancing research efforts towards viable drug candidates, which can be freely accessed at https://idrblab.org/drugfilter/.